Piper Sandler Maintains Overweight on Akoya Biosciences, Lowers Price Target to $11
Portfolio Pulse from Benzinga Newsdesk
Piper Sandler analyst David Westenberg has maintained an Overweight rating on Akoya Biosciences (NASDAQ:AKYA) but lowered the price target from $14 to $11.

October 16, 2023 | 5:18 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Piper Sandler has maintained an Overweight rating on Akoya Biosciences but lowered the price target from $14 to $11.
The news is directly about Akoya Biosciences and is likely to impact its stock price. While the Overweight rating is positive, the lowering of the price target may have a negative effect. However, the overall impact is neutral as the analyst still maintains a positive outlook on the company.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100